Saturday 17 October 2026
Export CERO’s income statement to Excel — free account
CERo Therapeutics Holdings, Inc.
CERO Healthcare Biotechnology
In the quarter to June 2026, EPS grew 98.9% and free cash flow grew 49.7%, each against the same quarter a year earlier.
0.01
0.00
0.00%
Follow CERO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 453.76% | 997.81% | 1,074.49% | 479.29% |
+8 more TTM periods Free account |
|
| (2,352.32%) | (1,882.18%) | (1,940.02%) | (945.67%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
310.09% | 1,002.88% | 1,564.17% | 880.42% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.29) | (0.50) | (3.80) | (10.92) | |
Free Cash Flow |
(12.10) | (14.40) | (16.08) | (13.81) | |
| Other line items | |||||
Cash ROIC |
41.99% | 174.19% | 424.94% | 547.93% | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(20.77) | (108.89) | — | — | |
Operating CF/Net income |
0.13 | 0.15 | 0.17 | 0.28 | |
Depreciation/Fixed assets |
14.70 | 6.67 | 4.41 | 3.48 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.29) | (0.50) | (3.80) | (10.92) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates